Logo

American Heart Association

  100
  0


Final ID: Tu041

Gut microbiome Bifidobacterium is associated with improvement in severity of heart failure with reduced ejection fraction

Abstract Body:
Background: Heart failure (HF) has been associated with dysregulated gut microbiome. However, less is understood about how gut microbiome alterations relate to changes in HF severity. We sought to understand how gut microbial shifts and associated host signatures related to changes in clinical status of patients with HF with reduced ejection fraction (HFrEF).
Methods: Twenty-six adults with HFrEF were recruited and completed 2 study visits approximately 6 months apart. At each visit they provided stool sample for microbiome profiling (metagenomic sequencing), and fasting blood samples for untargeted metabolomics (liquid chromatography–mass spectrometry) and cytokine assay (Luminex antibody-conjugated bead capture). Subjects also completed dietary surveys. Clinical improvement was measured as between-visit change in the New York Heart Association (NYHA) class.
Results: Between-visit NYHA class improved in 6 individuals; 20 patients remained stable or worsened. After accounting for demographics, body mass index, and diet, genus Bifidobacterium was significantly enriched in the improved group and increased over time (Figure 1). Bifidobacterium was directly associated with circulating malonic acid, which is implicated in cardio-protection and cardiomyocyte regeneration, and with indole-3-propionate (IPA), anti-inflammatory gut microbial metabolite of dietary tryptophan (Figure 2). There was also a positive correlation between Bifidobacterium and IL10, a major anti-inflammatory cytokine that plays a role in cardiac remodeling.
Conclusion: Bifidobacterium was independently associated with longitudinal improvement in functional status in patients with HFrEF. Additionally, Bifidobacterium correlated with circulating IPA, malonic acid, and IL10. Our findings support (1) gut Bifidobacterium as a potential biomarker of clinical improvement in HFrEF and a possible new therapeutic target, and (2) potential downstream mediators through which Bifidobacterium may regulate HF pathophysiology.
  • Mamic, Petra  ( Stanford University , Stanford , California , United States )
  • Shi, Handuo  ( Stanford University , Stanford , California , United States )
  • Tang, Wai Hong  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Sonnenburg, Justin  ( Stanford University , Stanford , California , United States )
  • Khush, Kiran  ( Stanford University , Stanford , California , United States )
  • Heidenreich, Paul  ( Stanford University , Stanford , California , United States )
  • Huang, Kerwyn  ( Stanford University , Stanford , California , United States )
  • Snyder, Michael  ( Stanford University , Stanford , California , United States )
  • Author Disclosures:
    Petra Mamic: DO NOT have relevant financial relationships | Handuo Shi: DO NOT have relevant financial relationships | Wai Hong Tang: DO have relevant financial relationships ; Consultant:Sequana Medical:Past (completed) ; Independent Contractor:Belvoir Media Group:Active (exists now) ; Independent Contractor:Springer:Active (exists now) ; Independent Contractor:American Board of Internal Medicine:Past (completed) ; Consultant:BioCardia:Active (exists now) ; Consultant:Salubris Biotherapeutics:Active (exists now) ; Consultant:WhiteSwell:Past (completed) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Alleviant Medical:Active (exists now) ; Consultant:Alexion Pharmaceuticals:Active (exists now) ; Consultant:CardiaTec Biosciences:Active (exists now) ; Consultant:Boston Scientific:Past (completed) ; Consultant:Zehna Therapeutics:Active (exists now) ; Consultant:Genomics plc:Past (completed) ; Consultant:Cardiol Therapeutics:Active (exists now) | Justin Sonnenburg: No Answer | Kiran Khush: DO have relevant financial relationships ; Consultant:CareDx, Inc.:Active (exists now) ; Consultant:Eledon Pharmaceuticals:Past (completed) ; Speaker:CareDx, Inc.:Active (exists now) | Paul Heidenreich: No Answer | Kerwyn Huang: No Answer | Michael Snyder: No Answer
Meeting Info:

Basic Cardiovascular Sciences

2024

Chicago, Illinois

Session Info:

Poster Session and Reception 2

Tuesday, 07/23/2024 , 04:30PM - 07:00PM

Poster Session and Reception

More abstracts on this topic:
Alternate Day Fasting Attenuates Arterial Thrombotic Risk via Increasing Indole-3-propionic acid

Feng Ruijia, Yang Wenchao, Peng Guiyan, Feng Weiqi, Long Ting, Li Zilun, Chang Guangqi, Huang Kan

Adult congenital heart disease (ACHD) as career? Examining encouraging and discouraging factors around the globe in the Global ACHD Survey.

Bravo-jaimes Katia, Elizari Maria Amalia, Valdez Ramos Miriam, Cupido Blanche, Zentner Dominica, Almasri Murad, Phillips Sabrina, Mcleod Christopher, Burchill Luke, Bullock-palmer Renee, Windram Jonathan, Srour Mhd Osama, Jenkins Petra, Luna-lopez Raquel, Tutarel Oktay, Kandavello Geetha, Guerrero Carlos, García Cruz Edgar, Ackerman Judith

You have to be authorized to contact abstract author. Please, Login
Not Available